What's all the hullabaloos about Aduhelm, the first new Alzheimer's drug approval since 2003? This month's MedEvidence guest, Dr. Steven Toenjes, MD, a board-certified neurologist, former staff neurologist in the U.S. Navy and an award-winning director of neurology residents at the Uniformed Services University of Health Sciences and decorated Navy veteran joins Dr. Michael Koren and Michelle McCormick to discuss the first new Alzheimer's drug approval since 2003 and the controversy over FDA's approval of Biogen's Aducanumab (Aduhelm).
Updated information on Medicare's decision to cover Alzheimer's drugs
Subscribe to MedEvidence! Podcast to be notified each Wednesday as new episodes are released.
Free Memory Screening
Be a part of advancing science by participating in research
Follow MedEvidence! on Social Media to discover the Truth Behind the Data.
Facebook
Instagram
Twitter
LinkedIn
Powered by ENCORE Research Group at www.ENCOREDOCS.com
Original Air Date: March 11, 2022
